lncRNA is one of the hottest and most cutting-edge subdivisions of basic biomedical research
By exploring lncRNA (long non-coding RNA), we can provide solutions to a wide range of unmet clinical needs. Led by Professor Xu Song, a pioneer in lncRNA research, lncTAC Bio has become an inventive company focusing on lncRNA drug development.
lncTAC Bio invented the advanced lncRNA based targeting chimera technology lncTAC® and the unique technology platform UNAST® for the development of innovative nucleic acid drugs for a wide range of traditionally undruggable targets.
lncTAC® & UNAST® — Owning full intelligence property
The technology developed by lncTAC Bio combines lncRNA with the most popular targeting chimera technology, which not only enhances the company's technology platform but also enables us to provide new innovative solutions for unmet clinical needs. Moreover, with the research and development of the UNAST® platform, we provide a solution for the nucleic acid drug instability and delivery difficulties.
Complementarity of the company's founding members
lncTAC Bio's founding members combine their strengths to quickly drive the company's growth. In the early stages, we additionally received support from local governments and a number of investment institutions.
-
01
Professor Xu Song, lncTAC Bio's founder, is one of the pioneers in lncRNA research worldwide. With 20 years of research experience, he can guide the research and development of new drugs to quickly reach the clinical stage.
-
02
Dr. Lihua Ding, co-founder and CEO, has held senior management roles in multinational pharmaceutical and innovative companies in China for more than 30 years. With his expertise and experience, he can lead the company and its projects to success.
-
03
Professor Chong Qin, co-founder, has been researching PROTAC for many years and is one of the inventors of the company's lncTAC® technology.
Unique and rich product pipeline
With two core technologies, lncTAC® and UNAST®, lncTAC Bio aims to provide solutions for a wide range of unmet clinical needs. In the next 3-5 years, more than 20 BIC/FIC products can be developed in the therapeutic fields of recurring cardiovascular disease (hyperlipidemia / hypertension), neurodegenerative disease (Alzheimer's / Parkinson's disease), and tumor (pancreatic / lung / colorectal cancer as well as multiple myeloma). The company plans to accelerate the commercialization by out-licensing and in-depth cooperation with domestic and multinational corporations for the authorized market development.
